课题基金 / 基金详情

GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES

GTP-BINDING PROTEIN STRUCTURE/FUNCTION STUDIES
GTP 结合蛋白结构/功能研究
批准号:
6162668
负责人:
M VAUGHAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

M VAUGHAN的其他基金

相似基金

相关文献

中文摘要
翻译
腺苷二磷酸核糖基化因子(ARF)是一种多功能、多结构域、 内质网和高尔基体中调控囊泡转运事件的蛋白质 以及通过与脂膜结合而在质膜上 被结合的GTP激活后。这种联系,促进了 ARF与效应器的相互作用[例如,囊泡外壳蛋白 β-COP被发现与I型高尔基体衍生的囊泡有关, G蛋白,或磷脂酶D(PLD)的特定异构体]和 将有助于发芽和囊泡的蛋白质募集到膜上 队形。急性呼吸道合并症是通过它们刺激霍乱的能力来确定的。 毒素ADP-核糖基转移酶活性。我们已经展示了使用嵌合体 来源于ARF1和人ARF样蛋白(ARL1)的蛋白质,它 仅最低限度地激活PLD,PLD激活位置位于 ARF1的1-73个氨基酸,CTA激活位点位于 残留物73-181。为了更准确地定义这些地点, 氨基末端截短的ARF、嵌合ARF和ARF点突变体 都是被建造的。ARF1的氨基末端截断到一定程度 显著降低了其激活PLD的能力,并未损害其 结合GTP的能力或增强霍乱毒素的活性 体外培养。嵌合蛋白ARF28ARL(N端28个氨基酸) 与ARL1的C端153个氨基酸相连的ARF1)的能力较弱 比ARF50ARL更能激活PLD。因此,28到50之间的氨基酸 在ARF和ARL上不同的基因,似乎参与了 可编程逻辑器件。具体而言,ARF中Lys38突变为Gln,相应的 ARL中的氨基酸产生ARF1(K38Q),但PLD活性降低。 相应的ARL突变体ARL1(Q38K)更能激活PLD 比ARL本身更有效。来自嵌合体的数据也缩小了 CTA激活区位于73-139位氨基酸之间。 总体而言,看起来至少有两个不同的线性区域 ARF序列参与了PLD的激活,第三个序列是 参与霍乱毒素ADP-核糖基转移酶的激活。因此, ARF是一种多结构域蛋白,涉及多个效应子。 互动。
英文摘要
ADP-ribosylation factors (ARFs) are multi-functional, multi-domain, proteins that regulate vesicular trafficking events in the ER and Golgi as well as at the plasma membrane by associating with a lipid membrane after becoming activated by binding GTP. This association, facilitates ARF interaction with effectors [e.g., the vesicular coat protein beta-COP found associated with type I Golgi-derived vesicles, the G-protein betagamma, or a specific isoform of phospholipase D (PLD)] and to recruit to membranes, proteins that contribute to budding and vesicle formation. ARFs were identified by their ability to stimulate cholera toxin ADP-ribosyltransferase activity. We had shown using chimeric proteins derived from ARF1 and human ARF-like protein (ARL1), which activates PLD only minimally, that the PLD activation site lies within amino acids 1-73 of ARF1, and the CTA activation site lies within residues 73-181. To define these sites more precisely, amino-terminally truncated ARFs, chimeric ARFs, and ARF point mutants were constructed. Amino-terminal truncation of ARF1 to an extent that significantly reduced its ability to activate PLD, did not impair its ability to bind GTP or to enhance the activity of cholera toxin in vitro. The chimeric protein ARF28ARL (the N-terminal 28 amino acids of ARF1 linked to the C-terminal 153 amino acids of ARL1) had less ability to activate PLD than did ARF50ARL. Thus, amino acids between 28 and 50 that differ in ARF and ARL, appear to be involved in the activation of PLD. Specifically, mutation of Lys38 in ARF to Gln, the corresponding amino acid in ARL, produced ARF1(K38Q) with diminished PLD activation. The corresponding ARL mutant, ARL1(Q38K), activated PLD much more effectively than did ARL itself. Data from the chimeras also narrowed the CTA activation domain to a region between amino acids 73 and 139. Overall, it appears that at least two different regions of the linear sequence of ARF are involved in the activation of PLD, and a third is involved in activation of cholera toxin ADP-ribosyltransferase. Thus, ARF is a multi-domain protein involved in multiple effector interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF GTP-BINDING PROTEIN
MOLECULAR AND BIOCHEMICAL CHARACTERIZATION OF GTP-BINDING PROTEIN
REGULATION OF GTP BINDING PROTEINS
REGULATION OF GTP BINDING PROTEINS
海外基金